Denali therapeutics reports first quarter 2025 financial results and business highlights including completion of bla rolling submission for tividenofusp alfa for hunter syndrome

South san francisco, calif., may 06, 2025 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli) today reported financial results for the first quarter ended march 31, 2025, and provided business highlights.
DNLI Ratings Summary
DNLI Quant Ranking